23,077 Shares in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Purchased by Y Intercept Hong Kong Ltd

Key Points

• Y Intercept Hong Kong Ltd has acquired a new stake in Arcturus Therapeutics Holdings Inc., purchasing 23,077 shares valued at approximately $244,000, representing a 0.09% ownership in the company.
• Institutional investors own about 94.54% of Arcturus Therapeutics' stock, with several hedge funds significantly increasing their positions in recent months.
• Despite a recent 3.0% drop in share price, Arcturus Therapeutics reported better-than-expected quarterly earnings and revenue, beating analyst estimates.

Y Intercept Hong Kong Ltd bought a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 23,077 shares of the biotechnology company's stock, valued at approximately $244,000. Y Intercept Hong Kong Ltd owned approximately 0.09% of Arcturus Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Wellington Management Group LLP lifted its stake in shares of Arcturus Therapeutics by 0.8% in the fourth quarter. Wellington Management Group LLP now owns 97,036 shares of the biotechnology company's stock valued at $1,647,000 after buying an additional 742 shares in the last quarter. Ameriprise Financial Inc. grew its position in shares of Arcturus Therapeutics by 5.0% during the 4th quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company's stock valued at $316,000 after acquiring an additional 883 shares during the period. Virtus ETF Advisers LLC grew its position in shares of Arcturus Therapeutics by 38.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock valued at $69,000 after acquiring an additional 1,132 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Arcturus Therapeutics by 7.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,018 shares of the biotechnology company's stock worth $323,000 after buying an additional 1,279 shares during the period. Finally, Byrne Asset Management LLC boosted its holdings in Arcturus Therapeutics by 89.8% in the 1st quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company's stock worth $31,000 after buying an additional 1,365 shares during the period. 94.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on ARCT. Wells Fargo & Company cut their price target on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Wall Street Zen cut shares of Arcturus Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, July 5th. Canaccord Genuity Group decreased their target price on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Citigroup reiterated a "buy" rating on shares of Arcturus Therapeutics in a research report on Tuesday, May 13th. Finally, Scotiabank reiterated an "outperform" rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Arcturus Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $54.00.

Arcturus Therapeutics Trading Up 0.7%

Shares of ARCT stock traded up $0.09 during mid-day trading on Friday, reaching $12.30. The stock had a trading volume of 361,584 shares, compared to its average volume of 381,998. The stock's 50-day moving average price is $13.17 and its two-hundred day moving average price is $13.48. Arcturus Therapeutics Holdings Inc. has a 52-week low of $8.04 and a 52-week high of $25.88. The firm has a market capitalization of $333.58 million, a PE ratio of -4.86 and a beta of 2.26. The company has a current ratio of 5.64, a quick ratio of 5.64 and a debt-to-equity ratio of 0.06.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.58) by $1.06. Arcturus Therapeutics had a negative net margin of 47.47% and a negative return on equity of 27.41%. The firm had revenue of $29.38 million for the quarter, compared to analysts' expectations of $25.64 million. Equities analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.